Ionis Pharmaceuticals reaffirms 2026 financial guidance in Regulation FD disclosure

Ionis Pharmaceuticals reaffirmed its previously announced financial guidance for the fiscal year ending December 31, 2026.

Key Highlights:

• Company states 2026 financial guidance remains unchanged from guidance issued April 29, 2026.
• Disclosure made under Item 7.01 as a Regulation FD update, not deemed “filed” under Exchange Act Section 18.
• Includes forward-looking statements subject to risks and uncertainties; company disclaims obligation to update them.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.